Taejun Pharmaceutical

What Taejun Pharmaceutical does

Taejun Pharmaceutical (태준제약) is a privately held Korean pharmaceutical manufacturer founded in 1978 and headquartered in Seoul's Yongsan-gu (Hannam-dong). With 251–500 employees, the company produces and markets prescription drugs across five therapeutic categories: ophthalmology (eye drops), gastrointestinal preparation (including the Suprep bowel preparation franchise), diagnostic contrast media, cardiovascular agents, and anti-infectives. Its products are distributed through Korean hospital pharmacies and retail pharmacy channels and are covered under the Korean national health insurance system.

The company generates revenue through two distinct go-to-market motions. The core prescription business sells reimbursed drugs through physician-prescribed channels, with revenue tied to formulary status, national insurance reimbursement, and physician adoption across hospital and retail pharmacy networks. A newer consumer health motion sells the Ocuared Plus and Ocuared G eye-health supplement line through dedicated e-commerce properties (accuzen.com, areds2eye.com), opening a direct-to-consumer, non-reimbursed revenue stream adjacent to its ophthalmology heritage.

Operationally, Taejun maintains export activities through a dedicated "글로벌태준" global section on its corporate website that lists overseas countries and export products, indicating a domestic-plus-international commercial structure. The company remains private with no disclosed funding rounds, M&A, or leadership changes in the available data, and it refreshed its corporate identity in January 2026 while continuing regulatory lifecycle management of its core franchises (e.g., the April 2026 Suprep product information update).

Name

Taejun Pharmaceutical

Legal name

(주) 태준제약

Website

https://taejoon.co.kr

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

251–500 employees

Short description

Taejun Pharmaceutical is a privately held Korean drug manufacturer founded in 1978, producing ophthalmology, gastrointestinal, contrast media, cardiovascular, and anti-infective prescription products for Korean hospitals and pharmacies, with export channels and a newer consumer eye-health supplement line.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Ophthalmic pharmaceuticals
• Gastrointestinal preparations
• Bowel cleansing solutions
• Prescription eye drops
• Diagnostic contrast agents

Headquarters

HQ city

Yongsan

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Sale of prescription and general pharmaceutical products including eye drops and gastrointestinal preparations through hospital and retail pharmacy channels

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Taejun Pharmaceutical manufactures and sells prescription pharmaceutical products focused on ophthalmology (eye drops for pupil dilation and dry eye treatment), gastrointestinal preparations (bowel cleansing solutions for colonoscopy and endoscopic procedures), and diagnostic contrast agents. The company also offers eye health nutritional supplements. Products are distributed to hospitals and retail pharmacies in South Korea, with selected export operations.

Product overview

Taejun Pharmaceutical is a Korean pharmaceutical company with a diversified portfolio of prescription and over-the-counter medications across multiple therapeutic categories. The product portfolio includes ophthalmology products (eye drops for pupil dilation and dry eye treatment), gastrointestinal/bowel preparation products (suprep and coolprep lines for colonoscopy preparation), and eye health nutritional supplements (ocuared line). Products are organized by therapeutic category including ophthalmology, digestive system, diagnostic agents (contrast media including gadolinium, barium, and iodine-based), cardiovascular medications, anti-infectives, and various other pharmaceutical categories. The company maintains both prescription-only (전문의약품) and prescription-requiring (일반의약품(처방)) product classifications.

Differentiator

Problem solved

Functional benefit

Products and services

• Myoct Eye Drops 0.1% (마이오텍트점안액0.1%) - Single-use Atropine sulfate eye drops (0.1%) for pupil dilation (cycloplegic/mydriatic agent), classified as a prescription-only ophthalmic medication for healthcare professionals and patients requiring pupil dilation.
• Myoct Eye Drops 0.05% (마이오텍트점안액0.05%) - Single-use Atropine sulfate eye drops (0.05%) for pupil dilation, a lower concentration variant of the Myoct ophthalmic line, classified as a prescription-only ophthalmic medication.
• Suprep Mini S Tablets (수프렙미니에스정) Bowel preparation medication for colon (X-ray, endoscopic) examination preparation, administered as a two-day split or same-day split dosing regimen for gastroenterologists and patients undergoing colonoscopy.
• Coolprep Gold Powder (쿨프렙골드산) Bowel cleansing powder for colonoscopy and barium X-ray examination preparation, containing polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, simethicone, and ascorbic acid. Available as A and B packs for solution preparation.
• Diquaday Eye Drops 5% (디쿠아데이점안액5%) - Single-use Diquafosol sodium eye drops (50mg/mL) for treating dry eye syndrome and related conjunctival epithelial disorders, administered as one drop three times daily. Classified as a prescription ophthalmic medication.
• Infresh F Eye Drops 1.5% (인프레쉬에프점안액1.5%) Carboxymethylcellulose sodium eye drops (1.5%) for lubricating and moisturizing dry eyes, classified as a prescription ophthalmic medication for patients with dry eye symptoms.
• Ocuared Plus (오큐아레즈투플러스) Nutritional supplement product for eye health support, marketed as an eye health functional food.
• Ocuared G (오큐아레즈투G) Eye health nutritional supplement product, marketed as an eye health functional food.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves2 records

Expansion highlights4 records

Broad incumbents

• Boryung Pharmaceutical: Mid-sized Korean pharma with prescription, OTC and consumer health lines including eye-care and GI products. Comparable to Taejun as a mid-market Korean multi-category drugmaker competing in overlapping domestic therapeutic segments.
• Allergan (AbbVie): Global ophthalmology leader (Restasis, Lumigan, Alphagan) post-AbbVie acquisition. Comparable as a broad incumbent defining therapeutic categories (notably dry eye) where Taejun's Diquaday and Infresh F compete for the same prescribers.
• Hanmi Pharmaceutical: Korea's largest domestic pharmaceutical company with deep ophthalmology (e.g., Cyclosporine A dry-eye franchise) and specialty-pharma portfolios, plus strong hospital and pharmacy channel coverage — directly comparable as a Korean pharma incumbent competing in the same prescription categories Taejun serves.
• Daewoong Pharmaceutical: Major Korean manufacturer with established ophthalmology, gastrointestinal and hospital-channel pharmaceutical franchises. Comparable to Taejun as a diversified Korean specialty pharma competing for the same hospital and retail pharmacy shelf space.
• Yuhan Corporation: Korea's largest pharmaceutical company by prescription sales with diversified portfolios across cardiovascular, GI, anti-infectives and ophthalmology. Comparable as a Korean multi-category prescription pharma selling through the same NHI-coded hospital and pharmacy channels.
• Dong-A Pharmaceutical: Large Korean pharma with a still-mix spanning ophthalmology (artificial tears and dry-eye line), GI preparations, and broad prescription distribution through Korean NHI. Directly comparable therapeutic mix and domestic channel strategy.
• Alcon: Largest dedicated ophthalmology company globally, spanning surgical, vision care and pharmaceutical eye drops. Comparable as the global benchmark for ophthalmology product breadth, though focused primarily on surgical/vision-care categories overlapping more loosely with Taejun's pharmaceutical eye drops.

Direct peers

• Senju Pharmaceutical: Japan-based specialty ophthalmology company focused on dry eye, anti-inflammatory and surgical eye care. Closely comparable as an Asia-anchored ophthalmology specialist chasing similar prescribers and NHI/reimbursement dynamics.
• Santen Pharmaceutical: Japan-headquartered global ophthalmology specialist with the strongest Asia-Pacific eye-drop franchise. Direct competitor to Taejun in prescription ophthalmology categories (dry eye, mydriatics, glaucoma) and the most relevant external benchmark for an Asia-focused eye-drop specialist.

Regional players

• Jeil Pharmaceutical: Korean specialty pharma with a focus on prescription ophthalmology and hospital-channel products. Comparable as a Korean mid-market ophthalmology peer with similar NHI-covered prescription eye-drop portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/taejoon-pharm.-co

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taejun Pharmaceutical